公开(公告)号：US20160222096A1

公开(公告)日：2016-08-04

申请号：US14981643

申请日：2015-12-28

Applicant: Genentech, Inc. ,  AIMM THERAPEUTICS B.V.

Inventor： Tim Beaumont ,  Mark Jeroen Kwakkenbos ,  Eric J. Brown ,  John Hiroshi Morisaki ,  Wouter L.W. Hazenbos ,  Sanjeev Mariathasan ,  Kimberly Kajihara ,  Yi Xia

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US09969795B2

公开(公告)日：2018-05-15

申请号：US14956919

申请日：2015-12-02

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Tim Beaumont ,  Mark Jeroen Kwakkenbos ,  Hergen Spits ,  Adrianus Quirinus Bakker ,  Koen Wagner

IPC: C07K16/00 ,  C07K16/10 ,  C07K14/47

CPC classification number: C07K16/1018 ,  C07K14/4703 ,  C07K14/4747 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.

公开(公告)号：US09688745B2

公开(公告)日：2017-06-27

申请号：US14981643

申请日：2015-12-28

Applicant: Genentech, Inc. ,  AIMM THERAPEUTICS B.V.

Inventor： Tim Beaumont ,  Mark Jeroen Kwakkenbos ,  Eric J. Brown ,  John Hiroshi Morisaki ,  Wouter L. W. Hazenbos ,  Sanjeev Mariathasan ,  Kimberly Kajihara ,  Yi Xia

IPC: C07K16/00 ,  C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US09266943B2

公开(公告)日：2016-02-23

申请号：US14103715

申请日：2013-12-11

Applicant: Genentech, Inc. ,  AIMM THERAPEUTICS B.V.

Inventor： Tim Beaumont ,  Mark Jeroen Kwakkenbos ,  Eric J. Brown ,  John Hiroshi Morisaki ,  Wouter L. W. Hazenbos ,  Sanjeev Mariathasan ,  Kimberly Kajihara ,  Yi Xia

IPC: A61K39/40 ,  C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US20170342134A1

公开(公告)日：2017-11-30

申请号：US15638820

申请日：2017-06-30

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Tim Beaumont ,  Etsuko Yasuda

IPC: C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/135

Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.

公开(公告)号：US09718876B2

公开(公告)日：2017-08-01

申请号：US14359291

申请日：2012-11-16

Applicant: AIMM Therapeutics B.V.

Inventor： Tim Beaumont ,  Etsuko Yasuda

IPC: C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/135

Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.

公开(公告)号：US09458228B2

公开(公告)日：2016-10-04

申请号：US14728826

申请日：2015-06-02

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim Beaumont ,  Mark Jeroen Kwakkenbos ,  Eric J. Brown ,  John Hiroshi Morisaki ,  Wouter L. W. Hazenbos ,  Sanjeev Mariathasan ,  Kimberly Kajihara ,  Yi Xia

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US20150004155A1

公开(公告)日：2015-01-01

申请号：US14359291

申请日：2012-11-16

Applicant: AIMM Therapeutics B.V.

Inventor： Tim Beaumont ,  Etsuko Yasuda

IPC: C07K16/10 ,  G01N33/569

CPC classification number: C07K16/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/135

Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.

Abstract translation: 本公开涉及对RSV G蛋白特异的人分离的，合成的或重组的抗体或其功能部分。 针对RSV G蛋白特异性的抗体特别适用于抵抗由RSV感染引起的RSV和诸如炎症的症状。 本公开还涉及这样的RSV G特异性抗体用于诊断RSV感染的用途，以及用于至少部分地治疗或缓解呼吸道合胞病毒感染和/或呼吸道合胞病毒感染症状的药物和/或预防剂 呼吸道合胞病毒相关疾病。

公开(公告)号：US10556963B2

公开(公告)日：2020-02-11

申请号：US15105076

申请日：2014-12-17

Applicant: AIMM Therapeutics B.V.

Inventor： Hergen Spits ,  Tim Beaumont ,  Marijn Aletta Gillissen ,  Adrianus Quirinus Bakker ,  Mette Deborah Hazenberg ,  Martijn Kedde

IPC: C07K16/30 ,  C07K16/06 ,  A61K47/68 ,  C07K16/40 ,  C12P21/00 ,  G01N33/574

Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

公开(公告)号：US10435463B2

公开(公告)日：2019-10-08

申请号：US15508570

申请日：2015-09-07

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Tim Beaumont ,  Sabrina Julia Louisa Merat ,  Cornelia Johanna Schinkel ,  Richard Molenkamp

IPC: C07K16/10

Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.